Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 19;3(2):111-115.
doi: 10.1159/000510799. eCollection 2020 Dec.

Cannabinoids and COVID-19

Myriam El Biali  1 , Barbara Broers  2 , Marie Besson  1 , Jules Demeules  1
Affiliations

Cannabinoids and COVID-19

Myriam El Biali et al. Med Cannabis Cannabinoids. .

Abstract

Since the endocannabinoid system is involved in immune function, the effect of cannabinoid intake on infectious conditions is questioned for several years and is of particular interest in the COVID 19 pandemia. Some data suggest that the immunomodulatory effect of cannabinoids may affect the course and severity of SARS-CoV-2 infection. Given the large number of cannabinoids consumers in the community, this commentary presents the current knowledge on the potential impact of cannabinoids and endocannabinoids on bacterial and viral infection courses namely SARS-CoV-2 disease. Practical recommendations, which can be drawn from the literature, are given.

Keywords: COVID-19; Cannabinoids; Endocannabinoid system; Immunity; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare. This commentary is based on an internal clinical guideline, available in French under: http://www.intrahug.ch/sites/intranet/files/structures/directions/communication/Coronavirus-COVID19/Recommandations-Institutionnelles/cannabinoides_et_covid-19.pdf.

References

    1. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020 Mar;7((1)):11. - PMC - PubMed
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb;395((10223)):497–506. - PMC - PubMed
    1. Chen C, Zhang XR, Ju ZY, He WF. Zhonghua Shao Shang Za Zhi. 2020;36((0)):E005. - PubMed
    1. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020 May;15((5)):700–4. - PMC - PubMed
    1. RAPPORT D'EXPERTISE INFECTIONS BACTERIENNES GRAVES (de la peau et des tissus mous, pleuro-pulmonaires, neurologiques et ORL) rapportées avec l'IBUPROFENE ou le KETOPROFENE dans le traitement symptomatique de la fièvre ou de douleur non rhumatologique. Marseille: CRPV Tours − CRPV Marseille; 2019 Feb